Top-Rated StocksTop-RatedNASDAQ:ASND Ascendis Pharma A/S (ASND) Stock Price, News & Analysis $247.05 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$247.18 +0.13 (+0.05%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ascendis Pharma A/S Stock (NASDAQ:ASND) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ascendis Pharma A/S alerts:Sign Up Key Stats Today's Range$243.91▼$249.9650-Day Range$215.54▼$249.8452-Week Range$153.49▼$250.74Volume450,896 shsAverage Volume739,020 shsMarket Capitalization$15.41 billionP/E Ratio28.49Dividend YieldN/APrice Target$295.39Consensus RatingBuy Company Overview Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia. The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S. Food and Drug Administration for the treatment of pediatric growth hormone deficiency. By transiently conjugating active hormone to a carrier molecule, the TransCon platform allows controlled release of the therapeutic agent over time, reducing injection frequency and helping to maintain more consistent drug exposure. Beyond growth hormone deficiency, Ascendis Pharma is advancing a pipeline of product candidates aimed at other rare endocrine disorders. TransCon parathyroid hormone (PTH) is in clinical development for hypoparathyroidism and has demonstrated positive proof‐of‐concept data. The company is also investigating TransCon CNP for the treatment of achondroplasia, a form of dwarfism, and pursuing additional indications in both endocrine and broader metabolic diseases. Ascendis Pharma’s management team brings together experienced professionals in drug development, regulatory affairs and commercial strategy. The company continues to expand its global footprint through strategic collaborations and partnerships, with the goal of delivering transformative therapies to patients with underserved conditions.AI Generated. May Contain Errors. Read More Ascendis Pharma A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreASND MarketRank™: Ascendis Pharma A/S scored higher than 71% of companies evaluated by MarketBeat, and ranked 223rd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingAscendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 16 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAscendis Pharma A/S has a consensus price target of $295.39, representing about 19.6% upside from its current price of $247.05.Amount of Analyst CoverageAscendis Pharma A/S has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ascendis Pharma A/S's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth-11.68% Earnings GrowthEarnings for Ascendis Pharma A/S are expected to decrease by -11.68% in the coming year, from $11.73 to $10.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is 28.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.78.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is 28.49, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.00.Price to Book Value per Share RatioAscendis Pharma A/S has a P/B Ratio of 26.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ascendis Pharma A/S's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.57% of the float of Ascendis Pharma A/S has been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 3.05, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ascendis Pharma A/S has recently decreased by 22.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.50 News SentimentAscendis Pharma A/S has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Ascendis Pharma A/S this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for ASND on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,641,015.00 in company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsAscendis Pharma A/S has minimal institutional ownership at this time.Read more about Ascendis Pharma A/S's insider trading history. Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASND Stock News HeadlinesAscendis Pharma A/S (NASDAQ:ASND) Receives Consensus Rating of "Buy" from BrokeragesMay 24 at 2:50 AM | americanbankingnews.comAscendis Pharma A/SMay 20, 2026 | money.usnews.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 25 at 1:00 AM | Weiss Ratings (Ad)Citigroup initiates coverage of Ascendis Pharma A (ASND) with buy recommendationMay 20, 2026 | msn.comAscendis Pharma (NASDAQ:ASND) Is Posting Healthy Earnings, But It Is Not All Good NewsMay 16, 2026 | finance.yahoo.comWhat to Know About This Fund’s $50 Million Exit From Ascendis PharmaMay 14, 2026 | fool.comFlemming Steen Jensen Sells 19,460 Shares of Ascendis Pharma A/S (NASDAQ:ASND) StockMay 14, 2026 | americanbankingnews.comInsider Selling: Ascendis Pharma A/S (NASDAQ:ASND) Insider Sells 19,460 Shares of StockMay 13, 2026 | insidertrades.comSee More Headlines ASND Stock Analysis - Frequently Asked Questions How have ASND shares performed this year? Ascendis Pharma A/S's stock was trading at $213.24 at the beginning of 2026. Since then, ASND stock has increased by 15.9% and is now trading at $247.05. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) released its earnings results on Thursday, May, 7th. The biotechnology company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.21 by $0.11. The biotechnology company had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. Read the conference call transcript. When did Ascendis Pharma A/S IPO? Ascendis Pharma A/S (ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager. Who are Ascendis Pharma A/S's major shareholders? Top institutional investors of Ascendis Pharma A/S include Principal Financial Group Inc. (1.44%), Spyglass Capital Management LLC (0.59%), Sei Investments Co. (0.56%) and Tri Locum Partners LP (0.41%). View institutional ownership trends. How do I buy shares of Ascendis Pharma A/S? Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD). Company Calendar Last Earnings5/07/2026Today5/25/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ASND's financial health is in the Green zone, according to TradeSmith. ASND has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASND CIK1612042 Webwww.ascendispharma.com Phone(457) 022-2244Fax45-3694-4010Employees1,189Year Founded2007Price Target and Rating Average Price Target for Ascendis Pharma A/S$295.39 High Price Target$355.00 Low Price Target$255.00 Potential Upside/Downside+19.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)$8.67 Trailing P/E Ratio28.49 Forward P/E Ratio21.06 P/E GrowthN/ANet Income-$258 million Net Margins57.87% Pretax Margin-19.73% Return on EquityN/A Return on Assets-8.37% Debt Debt-to-Equity Ratio0.79 Current Ratio1.00 Quick Ratio0.72 Sales & Book Value Annual Sales$814.57 million Price / Sales18.92 Cash FlowN/A Price / Cash FlowN/A Book Value$9.16 per share Price / Book26.97Miscellaneous Outstanding Shares62,380,000Free Float37,426,000Market Cap$15.41 billion OptionableOptionable Beta0.41 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ASND) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
